These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 26199720)

  • 1. Revisiting the 'self-medication' hypothesis in light of the new data linking low striatal dopamine to comorbid addictive behavior.
    Awad AG; Voruganti LL
    Ther Adv Psychopharmacol; 2015 Jun; 5(3):172-8. PubMed ID: 26199720
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Revisiting the Concept of Subjective Tolerability to Antipsychotic Medications in Schizophrenia and its Clinical and Research Implications: 30 Years Later.
    Awad AG
    CNS Drugs; 2019 Jan; 33(1):1-8. PubMed ID: 30511350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neuroleptic dysphoria: revisiting the concept 50 years later.
    Awad AG; Voruganti LN
    Acta Psychiatr Scand Suppl; 2005; (427):6-13. PubMed ID: 15877718
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Subjective and behavioural consequences of striatal dopamine depletion in schizophrenia--findings from an in vivo SPECT study.
    Voruganti LN; Awad AG
    Schizophr Res; 2006 Dec; 88(1-3):179-86. PubMed ID: 16949796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is neuroleptic dysphoria a variant of drug-induced extrapyramidal side effects?
    Voruganti LP; Awad AG
    Can J Psychiatry; 2004 May; 49(5):285-9. PubMed ID: 15198463
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuroleptic dysphoria: towards a new synthesis.
    Voruganti L; Awad AG
    Psychopharmacology (Berl); 2004 Jan; 171(2):121-32. PubMed ID: 14647964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Schizophrenia and addiction: An evaluation of the self-medication hypothesis].
    Potvin S; Stip E; Roy JY
    Encephale; 2003; 29(3 Pt 1):193-203. PubMed ID: 12876543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Is it time to consider comorbid substance abuse as a new indication for antipsychotic drug development?
    Awad AG
    J Psychopharmacol; 2012 Jul; 26(7):953-7. PubMed ID: 22170735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Subjective effects of AMPT-induced dopamine depletion in schizophrenia: correlation between dysphoric responses and striatal D(2) binding ratios on SPECT imaging.
    Voruganti L; Slomka P; Zabel P; Costa G; So A; Mattar A; Awad AG
    Neuropsychopharmacology; 2001 Nov; 25(5):642-50. PubMed ID: 11682247
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Addiction and schizophrenia.
    Batel P
    Eur Psychiatry; 2000 Mar; 15(2):115-22. PubMed ID: 10881208
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comorbidity and "self-medication".
    DuPont RL; Gold MS
    J Addict Dis; 2007; 26 Suppl 1():13-23. PubMed ID: 19283971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dopamine-Related Disruption of Functional Topography of Striatal Connections in Unmedicated Patients With Schizophrenia.
    Horga G; Cassidy CM; Xu X; Moore H; Slifstein M; Van Snellenberg JX; Abi-Dargham A
    JAMA Psychiatry; 2016 Aug; 73(8):862-70. PubMed ID: 27145361
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Compliance in schizophrenia: predictive factors, therapeutical considerations and research implications].
    Misdrahi D; Llorca PM; Lançon C; Bayle FJ
    Encephale; 2002; 28(3 Pt 1):266-72. PubMed ID: 12091789
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adverse subjective experience with antipsychotics and its relationship to striatal and extrastriatal D2 receptors: a PET study in schizophrenia.
    Mizrahi R; Rusjan P; Agid O; Graff A; Mamo DC; Zipursky RB; Kapur S
    Am J Psychiatry; 2007 Apr; 164(4):630-7. PubMed ID: 17403977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dopamine receptors and the dopamine hypothesis of schizophrenia.
    Seeman P
    Synapse; 1987; 1(2):133-52. PubMed ID: 2905529
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Striatal D(2/3) Binding Potential Values in Drug-Naïve First-Episode Schizophrenia Patients Correlate With Treatment Outcome.
    Wulff S; Pinborg LH; Svarer C; Jensen LT; Nielsen MØ; Allerup P; Bak N; Rasmussen H; Frandsen E; Rostrup E; Glenthøj BY
    Schizophr Bull; 2015 Sep; 41(5):1143-52. PubMed ID: 25698711
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of antipsychotic treatment on brain reward system reactivity in schizophrenia patients.
    Kirsch P; Ronshausen S; Mier D; Gallhofer B
    Pharmacopsychiatry; 2007 Sep; 40(5):196-8. PubMed ID: 17874350
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The self-medication hypothesis of substance use disorders: a reconsideration and recent applications.
    Khantzian EJ
    Harv Rev Psychiatry; 1997; 4(5):231-44. PubMed ID: 9385000
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Depressive symptoms and presynaptic dopamine function in neuroleptic-naive schizophrenia.
    Hietala J; Syvälahti E; Vilkman H; Vuorio K; Räkköläinen V; Bergman J; Haaparanta M; Solin O; Kuoppamäki M; Eronen E; Ruotsalainen U; Salokangas RK
    Schizophr Res; 1999 Jan; 35(1):41-50. PubMed ID: 9988840
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Striatal vs extrastriatal dopamine D2 receptors in antipsychotic response--a double-blind PET study in schizophrenia.
    Agid O; Mamo D; Ginovart N; Vitcu I; Wilson AA; Zipursky RB; Kapur S
    Neuropsychopharmacology; 2007 Jun; 32(6):1209-15. PubMed ID: 17077809
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.